Neurogene INC Form 4 insider transactions

Christine Mikail Cvijic, President and CFO of Neurogene Inc., sold 4,501 shares of common stock on March 13, 2025, to cover tax withholding obligations related to the vesting of a Restricted Stock Unit (RSU).

Samsara BioCapital, through its affiliated entities, has increased its holdings in Neurogene Inc. by purchasing additional shares at various price points on November 26, 2024.

Neurogene Inc.'s President and CFO, Christine Mikail Cvijic, purchased 24,000 shares of common stock at a weighted average price of $20.475.

Neurogene's CEO, Rachel McMinn, purchased 47,500 shares of common stock at an average price of $20.40 per share.

Director Robert Keith Woods acquired stock options to purchase 7,700 shares of Neurogene Inc. common stock on June 14, 2024.

Director Rohan Palekar acquired options to purchase 7,700 shares of Neurogene Inc. common stock on June 14, 2024.

Robert Baffi, a director of Neurogene Inc., was granted stock options to purchase 7,700 shares of common stock on June 14, 2024.

Director Sarah B. Noonberg acquired options to purchase 7,700 shares of Neurogene Inc. common stock on June 14, 2024.

Director Cory S. Freedland of Neurogene Inc. [NGNE] was granted stock options to purchase 7,700 shares of common stock on June 14, 2024.

Neurogene Inc. CEO Rachel McMinn reports the acquisition of employee stock options.

Christine Mikail, President and CFO of Neurogene Inc., reports the acquisition of stock options and a transaction involving common stock on March 13, 2024.

Neurogene Inc.'s Chief Scientific Officer, Stuart Cobb, reports acquisition of stock options and common stock.